Physician profile
Camille E Introcaso
NPI 1912067836
$22,749.88
in general payments reported to CMS, 2019-2025
30 companies · $822 in 2025
The $822 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,797 · 2020: $6,495 · 2021: $2,100 · 2022: $6,667 · 2023: $457 · 2024: $412 · 2025: $822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,591 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,590.94 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $18,313.45 | 2019-2025 | Valchlor |
| Genzyme Corporation | $1,832.82 | 2019-2025 | |
| Abbvie INC. | $521.41 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $217.53 | 2019-2025 | |
| Janssen Biotech, INC. | $180.34 | 2019-2025 | Tremfya |
| Pfizer INC. | $151.13 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $140.95 | 2019-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $138.12 | 2022-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $129.29 | 2019-2025 | |
| Lilly USA, LLC | $124.41 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Organon LLC | $117.12 | 2024-2025 | Hadlima, Vtama |
| Arcutis Biotherapeutics, INC. | $112.57 | 2024-2025 | Zoryve |
| Amgen INC. | $91.89 | 2020-2025 | Otezla |
| Galderma Laboratories, L.P. | $91.70 | 2019-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $85.45 | 2023-2025 | Sotyktu |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nobelpharma America, LLC | $78.51 | 2023-2025 | |
| Incyte Corporation | $67.31 | 2023-2025 | Opzelura |
| Ucb, INC. | $52.73 | 2019-2025 | Bimzelx |
| Celgene Corporation | $41.83 | 2019 | |
| Journey Medical Corporation | $41.72 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.29 | 2023-2024 | Spevigo |
| Allergan, INC. | $29.76 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $27.29 | 2019 | |
| Dusa Pharmaceuticals, INC. | $21.29 | 2019 | |
| Krystal Biotech INC | $21.04 | 2024 | Vyjuvek |
| Biofrontera INC. | $19.90 | 2019 | |
| Botanix Sb INC | $19.00 | 2025 | Sofdra |
| Sandoz INC. | $16.05 | 2023 | Hyrimoz |
| Fresenius Kabi USA, LLC | $14.98 | 2023 | Idacio |
| Dermavant Sciences, INC. | $14.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Camille Introcaso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.